Clinical Trial Search

Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo — 0.002; 0.203 Liters — p=0.0022

Primary: fMRI Intrinsic Connectivity: Default Mode Network — 0.40 units on a scale

Primary: Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) — 66.5 percentage of participants

Primary: 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987…

Primary: Average Change in Number of Luteinizing Hormone (LH) Pulses Over 10 Hours — 3.000 pulses per 10 hour period

Primary: Number of Participants With Treatment Emergent Adverse Events — 19 Participants

Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001

Primary: Montgomery-Asberg Depression Rating Scale — 12.50; 13.30 score on a scale

Primary: Maximum Tolerated Dose (MTD) of Pembrolizumab in Combination With Binimetinib Using the Standard 3+3 Design (Phase I) — 2; 0; 1; 6 Participants

Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 1; 6; 3 Number of Adverse Events

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 13; 8; 9; 3 Participants

Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681

Primary: Progression Free Survival — 4.23; 3.93 months — p=0.130

Primary: Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4 — 17.4; 37.0…

Primary: Proportion of Patients With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Specific Interest — 28; 27; 3; 3 Participants